A Novel Blood Proteomic Signature for Prostate Cancer - Archive ouverte HAL Access content directly
Journal Articles Cancers Year : 2023

A Novel Blood Proteomic Signature for Prostate Cancer

Abstract

Simple Summary Despite intensive research, effective tools for detection and monitoring of prostate cancer remain to be found. Prostate-specific antigen (PSA), commonly used in prostate cancer assessments, can lead to overdiagnosis and overtreatment of indolent disease. This highlights the need for supporting non-invasive diagnostic, prognostic, and disease stratification biomarkers that could complement PSA in clinical decision-taking via increased sensitivity and specificity. In order to address this need, we uncover novel prostate cancer protein signatures by leveraging a cutting-edge analytical technique to measure proteins in patient samples. This strategy was used as a discovery tool to identify changes in protein levels in the serum of newly diagnosed patients as compared with healthy controls; the feature set was then further validated by reference to a second cohort of patients, achieving a high discriminatory ability. The proteomic maps generated also identified relevant changes in biological functions, notably the complement cascade. Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.
Fichier principal
Vignette du fichier
cancers_15_01051_v2.pdf (1.59 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04058858 , version 1 (05-04-2023)

Licence

Attribution

Identifiers

Cite

Ammara Muazzam, Matt Spick, Olivier N. F. Cexus, Bethany Geary, Fowz Azhar, et al.. A Novel Blood Proteomic Signature for Prostate Cancer. Cancers, 2023, 15 (4), ⟨10.3390/cancers15041051⟩. ⟨hal-04058858⟩
26 View
45 Download

Altmetric

Share

Gmail Facebook X LinkedIn More